Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
mCTLs for refractory viral infections in PIDD
NCT02510404Phase 1Completed
- Sponsor
- Catherine Bollard
- Start
- Apr 2014
- Primary completion
- May 2019
- Modality
- Adoptive Cell Transfer
- Countries
- 1
01
Overview
Phase 1, open-label trial of multivirus-specific cytotoxic T lymphocytes in Epstein-Barr virus infection, cytomegalovirus infection (CMV) and adenovirus infection, sponsored by Catherine Bollard. Primary endpoint: Assessments of patients with adverse events after mCTLs infusion at 45 days. Started Apr 2014; status: completed.
02
Drugs
multivirus-specific cytotoxic T lymphocytes
03
Conditions
Epstein-Barr virus infectioncytomegalovirus infection (CMV)adenovirus infection
Beyond the preview
Go deeper on NCT02510404.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02510404.